Cagrilintide/semaglutide
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglu
Novo Nordisk · Phase 2 · Completed · Enrollment 626
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| CagriSema | Obesity + T2D | n/r | 35 | n/r | n/r |
| Semaglutide | Obesity + T2D | n/r | 35 | n/r | n/r |
| Cagrilintide | Obesity + T2D | n/r | 35 | n/r | n/r |
| Placebo | Obesity + T2D | n/r | 35 | n/r | n/r |